AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from management regarding ongoing investigations at its China subsidiary.

AstraZeneca said on Friday its triple-combination inhaler Breztri Aerosphere met all main goals in two late-stage trials for uncontrolled asthma, showing clinically meaningful improvement in lung ...

AstraZeneca's Fasenra, an injectable treatment for severe asthma, is more effective during attacks than the oral steroid that has been the standard of care for 50 years, cutting the need for ...

Step aside football, basketball and hockey, AstraZeneca is bringing its sports marketing efforts to the fastest-growing sport in America — pickleball. The pharma giant recently announced a partnership ...

AstraZeneca’s (AZN) Fasenra has been approved in the European Union, EU, as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis, EGPA.

AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. The injectable drug will serve as an official partner of the Professional ...

AstraZeneca may pay up to $15 billion for rights to Summit’s lung cancer drug, ivonescimab. Bob Duggan owns nearly 75% of Summit, which is valued at $17.4 billion. Get daily-updated rankings ...

Britain-based AstraZeneca's experimental drug selumetinib failed to show positive results in a late-stage clinical trial for lung cancer, according to Reuters.

LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of lung cancer, a step that will delay the drug’s arrival on the ...

AstraZeneca’s (AZN) Fasenra has been approved in the European Union, EU, as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...